---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-23-115285"
form_type: "8-K"
ticker: "DERM"
cik: "0001867066"
company_name: "Journey Medical Corp"
filed_at: "2023-11-07T23:59:59+00:00"
generated_at: "2026-06-08T17:38:38.893092+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# Journey Medical reports Q3 2023 net income of $16.8M vs loss a year ago; revenue up 114% YoY to $34.5M

## Summary
- GAAP net income $16.8M ($0.80 diluted) vs GAAP net loss $10.1M in Q3 2022.
- Total net revenue $34.5M, +114% YoY, including $19.0M upfront from Maruho license for Qbrexza in Asia.
- Adjusted EBITDA $20.8M ($0.99 diluted) vs -$4.0M in Q3 2022.
- Cost reduction to cut annual SG&A >$17M, surpassing prior $12M target; Q3 SG&A fell 45% to $8.6M.
- DFD-29 NDA for rosacea expected to be submitted to FDA around year-end 2023.

## SEC filing metadata
- accession: 0001104659-23-115285
- form_type: 8-K
- ticker: DERM
- cik: 0001867066
- company_name: Journey Medical Corp
- filed_at: 2023-11-07T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/0001104659-23-115285-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/tm2330064d1_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-23-115285
- JSON: https://secwatch.observer/filing/0001104659-23-115285.json
- Plain text: https://secwatch.observer/filing/0001104659-23-115285.txt

## Key facts
- Earnings Releases
  Journey Medical Corp reported third quarter ended September 30, 2023 results: revenue $34.5 million, net income $16.8 million, or $0.91 per share basic and $0.80 per share diluted, EPS $0.91 per share basic and $0.80 per share diluted.
  - Period: third quarter ended September 30, 2023
  - Revenue: $34.5 million
  - Net income: $16.8 million, or $0.91 per share basic and $0.80 per share diluted
  - EPS: $0.91 per share basic and $0.80 per share diluted
  - Result: reported results
  source text: Journey Medical Corporation Reports Third Quarter 2023 Financial Results and Recent Corporate Highlights Company generated total net revenues of $34.5 million in the third quarter of 2023, a 101% increase from $17.2 million in the second quarter of 2023 GAAP net income increased to $16.8 million, or $0.91 per share basic and $0.80 per share diluted, for the third quarter of 2023
  evidence_url: https://www.sec.gov/Archives/edgar/data/1867066/000110465923115285/0001104659-23-115285-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.